Pneumococcal Vaccine Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, Germany, UK, China - Size and Forecast 2023-2027

Pneumococcal Vaccine Market Forecast 2023-2027

The global pneumococcal vaccine market size is estimated to grow by USD 2.82 billion at a CAGR of 5.81% between 2022 and 2027. The introduction of pneumococcal vaccines has shown substantial potential in lowering the burden of pneumococcal disease. One of the key strategies for expanding immunization programs in developing countries is through augmented accessibility and availability of the pneumococcal vaccine. Also, education and awareness campaigns are important to expanding immunization programs. Furthermore, by engaging with local influencers and community-based organizations, awareness and acceptance of vaccines can be increased which can be done through community meetings, outreach programs, and partnerships with religious and community leaders. Therefore, expanding immunization programs by governments in developing countries is driving the growth of the global market during the forecast period.

It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historic data from 2017 to 2021, besides analyzing the current market scenario.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

Technavio has segmented the market into type, distribution channel, and geography.

• The type segment is classified into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine
• The distribution channel segment is classified into non-governmental organizations, government authorities, and distribution partner companies
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of the World (ROW)

Market Segmentation by Type, Distribution Channel and Geography Analysis

The Market is driven by the urgent need to combat pneumococcal Pneumonia and invasive pneumococcal infections, especially during a pandemic scenario. Extensive research activities and pipeline studies are ongoing to develop effective vaccines for the rising number of Pneumonia cases globally. Government awareness programs are crucial in promoting vaccination against novel pneumococcal strains and Streptococcus pneumoniae serotypes, particularly among vulnerable demographic groups. The market sees a demand for protein-based vaccines targeting the prominence of pneumococcal diseases, with an emphasis on immunization programs and vaccine accessibility. Pneumococcal strains affecting the Lungs, Bloodstream, Brain covering, and causing conditions like Sinusitis and Lung disease are driving the need for comprehensive pneumococcal vaccination strategies. Individuals with Chronic heart disease, Diabetes, certain cancers, and those with Human immunodeficiency are prioritized for vaccination due to increased susceptibility.

Type Analysis

Pneumococcal conjugate

The market share growth by the pneumococcal conjugate vaccine segment will be significant during the forecast period. The segment is developed to safeguard against various strains of the bacterium Streptococcus pneumoniae, which can cause serious ailments such as pneumonia, meningitis, and sepsis. In reducing the incidence of pneumonia, one of the significant advantages of the  conjugate vaccine.

Get a glance at the market contribution of various segments View a PDF Sample

The pneumococcal conjugate vaccine was the largest and was valued at USD 6.56 billion in 2017. This vaccine contains specific polysaccharides found on the surface of the Streptococcus pneumoniae bacterium, conjugated to a carrier protein. This conjugation improves the immune response, leading to robust and long-lasting protection against the targeted strains. To create an effective immunization product active voice is employed in the development and manufacturing of this segment. Therefore, such advantages are anticipated to boost the demand for the segment, which will fuel the growth of the segment in the market in focus during the forecast period.

Distribution Channel  Analysis

NGOs

Several NGOs, play a crucial role in the global market such as the Bill and Melinda Gates Foundation, the Global Alliance for Vaccines and Immunization, the United Nations Children's Fund, and Johns Hopkins University. The Pneumococcal Conjugate Vaccine (PCV) Access Coalition is a coalition of NGOs, academic institutions, and industry partners that aims to address barriers to pneumococcal immunization access. Such a coalition works towards assuring that high-quality pneumococcal vaccines are available and inexpensive for all populations, including those in low-income and marginalized settings. The pneumococcal conjugate vaccine access coalition facilitates knowledge sharing, collaboration, and resource mobilization to improve pneumococcal vaccine coverage globally through their collective efforts. Therefore, such advantages are anticipated to boost the demand for NGOs, which will fuel the growth of the NGOs segment in the global market during the forecast period.

Regional Analysis

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 41% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Over the years, North America has experienced significant growth in the demand for pneumococcal immunization owing to several factors such as the increasing prevalence of pneumococcal diseases, growing awareness about the significance of vaccination, and government initiatives to promote immunization.  According to the CDC, pneumococcal disease is responsible for around 150,000 cases of invasive disease and approximately 3250 deaths yearly in the US alone. 

In addition, pharmaceutical companies based in the region are actively involved in developing and commercializing new pneumococcal immunization. For instance, in June 2021, Pfizer Inc (Pfizer), a renowned pharmaceutical company in the US, developed Prevnar 13, a widely used pneumococcal conjugate vaccine that was approved by the US FDA.  Therefore, such innovative vaccines improve market growth and create further opportunities in the region, which in turn drive the market growth in the region during the forecast period.

Buy Now Full Report and Discover More

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 15 market companies, including:

Astellas Pharma Inc. - The company offers pneumococcal immunization solutions such as the Multiple Antigen Presenting System to advance a novel MAPS vaccine targeted to prevent and reduce the spread of Streptococcus pneumoniae disease.

CSL Ltd. - The company offers pneumococcal vaccines such as 14-valent paediatric Pneumococcal Conjugate Vaccine, (Investigational Pneumococcal Polysaccharide Conjugate Vaccine PCV14) against S. pneumoniae infection.

GlaxoSmithKline Plc - The company offers pneumococcal vaccines such as PNEUMOVAX 23 for the prevention of pneumococcal disease caused by infection with pneumococcal types included in the vaccine.

• Merck and Co. Inc.
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Shenzhen Kangtai Biological Products Co. Ltd.
• Sinovac Biotech Ltd., SK Inc.
• Biological E. Ltd.
• Inventprise Inc.
• Petrovax
• Vaxcyte Inc.
• Walvax Biotechnology Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The Market is driven by the urgent need to combat pneumococcal Pneumonia and invasive pneumococcal infections, particularly during a pandemic. Research activities and pipeline studies are accelerating vaccine development, with a focus on novel pneumococcal strains and Streptococcus pneumoniae serotypes. Challenges include addressing economic disparities affecting vaccine accessibility and ensuring immunization programs reach vulnerable demographic groups. Trends indicate a shift towards protein-based vaccines and advancements in vaccine manufacturing. Despite progress, reducing hospitalizations and mortality rates remains a critical challenge. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. 

Significant Market Trends

Advancements in vaccine technologies are an emerging trend shaping the market growth. In vaccine technologies, the global market has experienced substantial advancements. As a result of such developments, they have led to the creation of more effective and efficient vaccines. This contributed to the prevention and control of pneumococcal diseases worldwide. Also, the advancements in vaccine technologies have led to the development of next-generation vaccines. The use of nanoparticle-based vaccines is one example, where tiny particles are engineered to carry antigens that stimulate the immune system. These nanoparticles offer various benefits, such as improved immune response and enhanced stability.

Further, they can be easily modified to target specific serotypes. This targeted approach enables a more tailored and effective immune response, which leads to better protection against pneumococcal diseases. Therefore, such factors are anticipated to augment the demand for pneumococcal vaccines, which will fuel the growth of the global market during the forecast period.

Major Market Challenges

The high cost of vaccine development and production is a significant challenge hindering market growth. In the global market, the high cost of vaccine development and production is a significant challenge. Developing and bringing a vaccine to market requires significant financial investment owing to several aspects, including R&D, clinical trials, regulatory approvals, manufacturing facilities, and distribution. Such costs majorly contribute to the high price of pneumococcal vaccines. Also, vaccine manufacturing facilities contribute to the high cost and these facilities must stick to stringent quality control measures and hold a sterile environment to assure the security and efficacy of vaccines. 

Further, manufacturing vaccines contains intricate procedures such as culturing microorganisms, purifying antigens, formulating vaccines, and packaging them, all of which need specialized equipment and materials. Distribution costs further compound the expenses.  Therefore, these factors are anticipated to impede the growth of the market during the forecast period.

Buy Now Full Report and Discover More

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

• Type Outlook 
  • Pneumococcal conjugate vaccine
  • Pneumococcal polysaccharide vaccine

• Distribution Channel Outlook
  • Non-governmental organizations
  • Government authorities
  • Distribution partner companies

• Region Outlook 
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest Of the World (ROW)
    • Australia
    • Brazil
    • Argentina

Market Analyst Overview

The Market is vital in addressing contagious disease burdens, especially among vulnerable populations such as Pneumonia patients, Immunocompromised patients, and the geriatric population. One crucial aspect is the administration of booster doses to ensure long-term immunity, particularly for individuals who have undergone Splenectomy or those with specific medical conditions like Certain types of cancer. Routes of administration are diverse, ranging from Pharmacies to Community clinics, catering to various age groups, including Pediatrics and adults. The market emphasizes collaborations with organizations like the American Lung Association to promote awareness and vaccination drives, reducing hospitalizations and mortality rates associated with Bacterial meningitis and other pneumococcal infections.

Moreover, symptoms such as Redness, Headache, Tiredness, and Generalized muscle weakness can indicate Bacterial meningitis, necessitating immediate vaccination efforts. However, challenges persist due to economic disparities affecting vaccine accessibility, highlighting the need for targeted interventions and government initiatives. The growth of the market is influenced by booster doses, Routes of administration, Streptococcus pneumonia, Certain types of cancer, and Generalized muscle. The Market continues to evolve with advancements in vaccine development, focusing on efficacy, safety, and reaching underserved populations to mitigate the impact of pneumococcal infections and improve public health outcomes.

Market Scope
Report Coverage	Details
Page number	155
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 5.81%
Market growth 2023-2027	USD 2.82 billion
Market structure	Fragmented
YoY growth 2022-2023(%)	5.09
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 41%
Key countries	US, Canada, Germany, UK, and China
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Astellas Pharma Inc., CSL Ltd., GlaxoSmithKline Plc, Merck and Co. Inc., Panacea Biotec Ltd., Pfizer Inc., Sanofi, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Sinovac Biotech Ltd., SK Inc., Biological E. Ltd., Inventprise Inc., Petrovax, Vaxcyte Inc., and Walvax Biotechnology Co. Ltd.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the market  between 2023 and 2027
• Precise estimation of the market size and its contribution to the market in focus on the parent market
• Detailed market growth analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on the company's position and classification
• Accurate predictions about upcoming trends and changes in consumer behaviour
• Growth of the market across North America, Europe, Asia, and the Rest of the World (ROW)
• A thorough market research and growth analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive market growth and forecasting analysis of factors that will challenge the growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch